Kiniksa Pharmaceuticals financials at a glance

+ Portfolio

The revenue of Kiniksa Pharmaceuticals is reported as 0.27026 billion Dollars in the fiscal year 2023. The earnings were 0.2 Dollars per share in 2023, which was 92.31 lower than 2022. And about 0.01317 billion Dollars are reported as free cash flow in the financials of Kiniksa Pharmaceuticals 2023. No dividends were paid to the shareholders of the Kiniksa Pharmaceuticals stock NasdaqGS:KNSA in the financial year 2023.

$270.26M

Revenue

$0.20

Earnings Per Share

66.72%

Gross Margin %

$-11.00M

Free Cash Flow

Revenue

270.26

Earnings Per Share

0.20

Gross Margin %

66.72

Free Cash Flow

-11.00

Financials

Year	Year	TTM	2023	2022	2021	2020	2019	2018	2017
Rev.	Revenue	N/A	$270.26M	$220.18M	$38.54M	$0.00M	$0.00M	$0.00M	$0.00M
GM %	Gross Margin %	68.79%	66.72%	78.67%	74.22%	0.00%	0.00%	0.00%	0.00%
OM	Operating Margin	-7.73%	-9.32%	4.44%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-0.10	$0.20	$2.60	$-2.29	$-2.61	$-2.99	$-3.49	$-2.73
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	0.00%	0.00%	-0.00%	-0.00%	-0.00%	-0.00%	0
Sha.	Shares	N/AM	70.62M	69.75M	69.1M	68.23M	55.55M	54.33M	4.29M
OCF	Operating Cash Flow	N/A	$13.30M	$5.81M	$-,126.30M	$-,136.53M	$-,158.37M	$-81.01M	$0.00M
FCF	Free Cash Flow	N/A	$-11.00M	$5.70M	$-,126.71M	$-,136.82M	$-,161.57M	$-86.30M	$0.00M
FCFS	Free Cash Flow Per Share	$-0.04	$0.19	$0.08	$-2.14	$-2.21	$-2.99	$-2.92	$-27.79

Kiniksa Pharmaceuticals financials at a glance

Financials

Discover